WTO Exemptions To Give Leg-Up To Bangladeshi, Indian Firms?
This article was originally published in PharmAsia News
Executive Summary
The WTO Council's recent decision to grant least-developed country members an exemption from implementing intellectual property provisions, such as patents, on medicines is expected to give Bangladesh's up-and-coming pharma industry valuable buffer time to catch up with and possibly take on rivals in the region.
You may also be interested in...
Bangladesh HCV Market: Can Generic Epclusa Shake Things Up?
Bangladesh's HCV market report card currently reads along these lines: generic versions of Sovaldi and Daklinza have made significant gains leaving interferon by the wayside, while generic Harvoni has had a quiet run. But, the arrival of cut-price Epclusa generics could bring change, besides putting the spotlight on the growing prowess of the South Asian nation's pharmaceutical industry.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet